Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria

Drug Resistance Updates

Volumn 27, Issue , 2016, Pages 59-71

  Hwang, In Young ^a,b   Koh, Elvin ^b,c   Kim, Hye Rim ^a,b   Yew, Wen Shan ^a,b,c   Chang, Matthew Wook ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antibiotic resistant pathogen; Bacteriocin; Microbiota; Prophylactic agent; Synthetic biology

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; DRUG EFFICACY; DRUG MECHANISM; GENETIC ENGINEERING; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIUM; BIOSYNTHESIS; CELL ENGINEERING; DRUG EFFECTS; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; GENETICS; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; CELL ENGINEERING; DRUG RESISTANCE, BACTERIAL; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS;

EID: 84977097737     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2016.06.002     Document Type: Review

References (100)

1. Andersson, M.I., MacGowan, A.P., Development of the quinolones. J. Antimicrob. Chemother. 51:Suppl. 1 (2003), 1–11.
2. Andriole, V.T., The quinolones: past, present, and future. Clin. Infect. Dis. 41 (2005), S113–S119.
3. Arthur, T.D., Cavera, V.L., Chikindas, M.L., On bacteriocin delivery systems and potential applications. Future Microbiol. 9 (2014), 235–248.
4. Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., Fischetti, V.A., Marraffini, L.A., Exploiting CRISPR–Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32 (2014), 1146–1150.
5. Borody, T.J., Brandt, L.J., Paramsothy, S., Therapeutic faecal microbiota transplantation: current status and future developments. Curr. Opin. Gastroenterol. 30 (2014), 97–105.
6. Borrero, J., Chen, Y., Dunny, G.M., Kaznessis, Y.N., Modified lactic acid bacteria detect and inhibit multiresistant enterococci. ACS Synth. Biol. 4 (2015), 299–306.
7. Brumfitt, W., Salton, M.R., Hamilton-Miller, J.M., Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 50 (2002), 731–734.
8. Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., Littmann, E., van den Brink, M.R.M., Jenq, R.R., Taur, Y., Sander, C., Cross, J., Toussaint, N.C., Xavier, J.B., Pamer, E.G., Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
9. Cascales, E., Buchanan, S.K., Duché, D., Kleanthous, C., Lloubès, R., Postle, K., Riley, M., Slatin, S., Cavard, D., Colicin biology. Microbiol. Mol. Biol. Rev.: MMBR 71 (2007), 158–229.
10. Cavera, V.L., Arthur, T.D., Kashtanov, D., Chikindas, M.L., Bacteriocins and their position in the next wave of conventional antibiotics. Int. J. Antimicrob. Agents 46 (2015), 494–501.
11. Chaisson, R.E., Treatment of chronic infections with rifamycins: is resistance likely to follow?. Antimicrob. Agents Chemother. 47 (2003), 3037–3039.
12. Chinchilla, M., Pasetti, M.F., Medina-Moreno, S., Wang, J.Y., Gomez-Duarte, O.G., Stout, R., Levine, M.M., Galen, J.E., Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect. Immun. 75 (2007), 3769–3779.
13. Citorik, R.J., Mimee, M., Lu, T.K., Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol., 2014, 1–7.
14. Collin, F., Thompson, R.E., Jolliffe, K.A., Payne, R.J., Maxwell, A., Fragments of the bacterial toxin microcin B17 as gyrase poisons. PLOS ONE, 8, 2013, e61459.
15. Cosgrove, S.E., Kaye, K.S., Eliopoulous, G.M., Carmeli, Y., Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. 162 (2002), 185–190.
16. Cotter, P.D., Ross, R.P., Hill, C., Bacteriocins – a viable alternative to antibiotics?. Nat. Rev. Microbiol. 11 (2013), 95–105.
17. Courvalin, P., Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42 (2006), S25–S34.
18. de Vos, W.M., Fame and future of faecal transplantations – developing next-generation therapies with synthetic microbiomes. Microb. Biotechnol. 6 (2013), 316–325.
19. Delves-Broughton, J., Blackburn, P., Evans, R.J., Hugenholtz, J., Applications of the bacteriocin, nisin. Ant. Leeuwenhoek 69 (1996), 193–202.
20. Drider, D., Rebuffat, S., Prokaryotic Antimicrobial Peptides: From Genes to Applications. 2011, Springer Verlag, New York.
21. Duan, F.P., March, J.C., Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 11260–11264.
22. Dyke, K.G., Jevons, M.P., Parker, M.T., Penicillinase production and intrinsic resistance to penicillins in Staphylococcus aures. Lancet 1 (1966), 835–838.
23. Essack, S.Y., The development of beta-lactam antibiotics in response to the evolution of beta-lactamases. Pharm. Res. 18 (2001), 1391–1399.
24. Evans, D.T., Chen, L.M., Gillis, J., Lin, K.C., Harty, B., Mazzara, G.P., Donis, R.O., Mansfield, K.G., Lifson, J.D., Desrosiers, R.C., Galan, J.E., Johnson, R.P., Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J. Virol. 77 (2003), 2400–2409.
25. Fabrega, A., Madurga, S., Giralt, E., Vila, J., Mechanism of action of and resistance to quinolones. Microbiol. Biotechnol. 2 (2009), 40–61.
26. Fernandez, M., Conde, S., de la Torre, J., Molina-Santiago, C., Ramos, J.L., Duque, E., Mechanisms of resistance to chloramphenicol in Pseudomonas putida KT2440. Antimicrob. Agents Chemother. 56 (2012), 1001–1009.
27. Focareta, A., Paton, J.C., Morona, R., Cook, J., Paton, A.W., A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 130 (2006), 1688–1695.
28. Friedman, N.D., Antimicrobial stewardship: the need to cover all bases. Antibiotics 2 (2013), 400–418.
29. Goldstein, B.P., Wei, J., Greenberg, K., Novick, R., Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J. Antimicrob. Chemother. 42 (1998), 277–278.
30. Gough, E., Shaikh, H., Manges, A.R., Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53 (2011), 994–1002.
31. Grehan, M.J., Borody, T.J., Leis, S.M., Campbell, J., Mitchell, H., Wettstein, A., Durable alteration of the colonic microbiota by the administration of donor fecal flora. J. Clin. Gastroenterol. 44 (2010), 551–561.
32. Gupta, S., Bram, E.E., Weiss, R., Genetically programmable pathogen sense and destroy. ACS Synth. Biol. 2 (2013), 715–723.
33. Hawkey, P.M., Mechanisms of quinolone action and microbial response. J. Antimicrob. Chemother. 51 (2003), 29–35.
34. Hernani Mde, L., Ferreira, P.C., Ferreira, D.M., Miyaji, E.N., Ho, P.L., Oliveira, M.L., Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunol. Med. Microbiol. 62 (2011), 263–272.
35. Holmes, A.H., Moore, L.S., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., Guerin, P.J., Piddock, L.J., Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 387 (2016), 176–187.
36. Hooper, D.C., Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31 (2000), S24–S28.
37. Hwang, I.Y., Tan, M.H., Koh, E., Ho, C.L., Poh, C.L., Chang, M.W., Reprogramming microbes to be a pathogen-seeking killer. ACS Synth. Biol. 3 (2014), 228–237.
38. Juárez-Rodríguez, M.D., Arteaga-Cortés, L.T., Kader, R., Curtiss, R., Clark-Curtiss, J.E., Live attenuated Salmonella vaccines against mycobacterium tuberculosis with antigen delivery via the Type III secretion system. Infect. Immun. 80 (2012), 798–814.
39. Kaplan, J.B., LoVetri, K., Cardona, S.T., Madhyastha, S., Sadovskaya, I., Jabbouri, S., Izano, E.A., Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J. Antibiot. 65 (2012), 73–77.
40. Kohanski, M.A., Dwyer, D.J., Hayete, B., Lawrence, C.A., Collins, J.J., A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130 (2007), 797–810.
41. Kolodkin-Gal, I., Romero, D., Cao, S., Clardy, J., Kolter, R., Losick, R., D-amino acids trigger biofilm disassembly. Science 328 (2010), 627–629.
42. Koo, O.K., Amalaradjou, M.A., Bhunia, A.K., Recombinant probiotic expressing Listeria adhesion protein attenuates Listeria monocytogenes virulence in vitro. PLoS ONE, 7, 2012, e29277.
43. Lawley, T.D., Clare, S., Walker, A.W., Stares, M.D., Connor, T.R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., Deakin, L.J., Pickard, D.J., Duncan, S.H., Flint, H.J., Clark, T.G., Parkhill, J., Dougan, G., Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog., 8, 2012, e1002995.
44. Levine, M.M., Tacket, C.O., Sztein, M.B., Host–Salmonella interaction: human trials. Microbes Infect. 3 (2001), 1271–1279.
45. Lewis, K., Persister cells. Annu. Rev. Microbiol. 64 (2010), 357–372.
46. Lewis, K., Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12 (2013), 371–387.
47. Lichtman, J.S., Ferreyra, J.A., Ng, K.M., Smits, S.A., Sonnenburg, J.L., Elias, J.E., Host–microbiota interactions in the pathogenesis of antibiotic-associated diseases. Cell Rep. 14 (2016), 1049–1061.
48. Lin, Y.H., Xu, J.L., Hu, J., Wang, L.H., Ong, S.L., Leadbetter, J.R., Zhang, L.H., Acyl-homoserine lactone acylase from Ralstonia strain XJ12B represents a novel and potent class of quorum-quenching enzymes. Mol. Microbiol. 47 (2003), 849–860.
49. Ling, H., Saeidi, N., Rasouliha, B.H., Chang, M.W., A predicted S-type pyocin shows a bactericidal activity against clinical Pseudomonas aeruginosa isolates through membrane damage. FEBS Lett. 584 (2010), 3354–3358.
50. Livermore, D.M., Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin. Infect. Dis. 34 (2002), 634–640.
51. Lu, T.K., Collins, J.J., Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 11197–11202.
52. Lu, T.K., Collins, J.J., Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 4629–4634.
53. Maldonado-Barragan, A., Cardenas, N., Martinez, B., Ruiz-Barba, J.L., Fernandez-Garayzabal, J.F., Rodriguez, J.M., Gibello, A., Garvicin A, a novel class IId bacteriocin from Lactococcus garvieae that inhibits septum formation in L. garvieae strains. Appl. Environ. Microbiol. 79 (2013), 4336–4346.
54. Martínez, J.L., Alonso, A., Gómez-Gómez, J.M., Baquero, F., Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?. J. Antimicrob. Chemother. 42 (1998), 683–688.
55. Martinez-Martinez, L., Pascual, A., Jacoby, G.A., Quinolone resistance from a transferable plasmid. Lancet 351 (1998), 797–799.
56. Merril, C.R., Scholl, D., Adhya, S.L., The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug. Discov. 2 (2003), 489–497.
57. Metlitskaya, A., Kazakov, T., Kommer, A., Pavlova, O., Praetorius-Ibba, M., Ibba, M., Krasheninnikov, I., Kolb, V., Khmel, I., Severinov, K., Aspartyl-tRNA synthetase is the target of peptide nucleotide antibiotic Microcin C. J. Biol. Chem. 281 (2006), 18033–18042.
58. Mingeot-Leclercq, M.-P., Glupczynski, Y., Tulkens, P.M., Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 43 (1999), 727–737.
59. Moellering, R.C., Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 42 (2006), S3–S4.
60. Mota-Meira, M., LaPointe, G., Lacroix, C., Lavoie, M.C., MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob. Agents Chemother. 44 (2000), 24–29.
61. Ng, C.L., Lang, K., Meenan, N.A., Sharma, A., Kelley, A.C., Kleanthous, C., Ramakrishnan, V., Structural basis for 16S ribosomal RNA cleavage by the cytotoxic domain of colicin E3. Nat. Struct. Mol. Biol. 17 (2010), 1241–1246.
62. Nishikawa, H., Sato, E., Briones, G., Chen, L.M., Matsuo, M., Nagata, Y., Ritter, G., Jager, E., Nomura, H., Kondo, S., Tawara, I., Kato, T., Shiku, H., Old, L.J., Galan, J.E., Gnjatic, S., In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 116 (2006), 1946–1954.
63. Nordmann, P., Poirel, L., Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J. Antimicrob. Chemother. 56 (2005), 463–469.
64. Pandey, N., Malik, R.K., Kaushik, J.K., Singroha, G., Gassericin A: a circular bacteriocin produced by lactic acid bacteria Lactobacillus gasseri. World J. Microbiol. Biotechnol. 29 (2013), 1977–1987.
65. Papagianni, M., Anastasiadou, S., Pediocins: the bacteriocins of pediococci. Sources, production, properties and applications. Microb. Cell Fact., 8, 2009, 3.
66. Papaioannou, E., Wahjudi, M., Nadal-Jimenez, P., Koch, G., Setroikromo, R., Quax, W.J., Quorum-quenching acylase reduces the virulence of Pseudomonas aeruginosa in a Caenorhabditis elegans infection model. Antimicrob. Agents Chemother. 53 (2009), 4891–4897.
67. Patel, J.C., Galan, J.E., Manipulation of the host actin cytoskeleton by Salmonella – all in the name of entry. Curr. Opin. Microbiol. 8 (2005), 10–15.
68. Paton, A.W., Jennings, M.P., Morona, R., Wang, H., Focareta, A., Roddam, L.F., Paton, J.C., Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 128 (2005), 1219–1228.
69. Petrof, E.O., Gloor, G.B., Vanner, S.J., Weese, S.J., Carter, D., Daigneault, M.C., Brown, E.M., Schroeter, K., Allen-Vercoe, E., Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome, 1, 2013, 3.
70. Piper, C., Draper, L.A., Cotter, P.D., Ross, R.P., Hill, C., A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J. Antimicrob. Chemother. 64 (2009), 546–551.
71. Rasmussen, T.B., Givskov, M., Quorum-sensing inhibitors as anti-pathogenic drugs. Int. J. Med. Microbiol.: IJMM 296 (2006), 149–161.
72. Reimmann, C., Ginet, N., Michel, L., Keel, C., Michaux, P., Krishnapillai, V., Zala, M., Heurlier, K., Triandafillu, K., Harms, H., Defago, G., Haas, D., Genetically programmed autoinducer destruction reduces virulence gene expression and swarming motility in Pseudomonas aeruginosa PAO1. Microbiology 148 (2002), 923–932.
73. Rishi, P., Preet, S., Kaur, P., Effect of L. plantarum cell-free extract and co-trimoxazole against Salmonella Typhimurium: a possible adjunct therapy. Ann. Clin. Microbiol. Antimicrob., 10, 2011, 9.
74. Roberts, R.R., Hota, B., Ahmad, I., Scott, R.D. 2nd, Foster, S.D., Abbasi, F., Schabowski, S., Kampe, L.M., Ciavarella, G.G., Supino, M., Naples, J., Cordell, R., Levy, S.B., Weinstein, R.A., Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. 49 (2009), 1175–1184.
75. Robicsek, A., Jacoby, G.A., Hooper, D.C., The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6 (2006), 629–640.
76. Russmann, H., Igwe, E.I., Sauer, J., Hardt, W.D., Bubert, A., Geginat, G., Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J. Immunol. 167 (2001), 357–365.
77. Saeidi, N., Wong, C.K., Lo, T.M., Nguyen, H.X., Ling, H., Leong, S.S., Poh, C.L., Chang, M.W., Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. Mol. Syst. Biol., 7, 2011, 521.
78. Sanchez, B., Lopez, P., Gonzalez-Rodriguez, I., Suarez, A., Margolles, A., Urdaci, M.C., A flagellin-producing Lactococcus strain: interactions with mucin and enteropathogens. FEMS Microbiol. Lett. 318 (2011), 101–107.
79. Sartor, R.B., Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008), 577–594.
80. Shams, H., Poblete, F., Russmann, H., Galan, J.E., Donis, R.O., Induction of specific CD8+ memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope. Vaccine 20 (2001), 577–585.
81. Singh, A.P., Preet, S., Rishi, P., Augmentation of antimicrobial activity of conventional antibiotics by cell-free extract of L. plantarum. J. Antibiot. 64 (2011), 795–798.
82. Sio, C.F., Otten, L.G., Cool, R.H., Diggle, S.P., Braun, P.G., Bos, R., Daykin, M., Camara, M., Williams, P., Quax, W.J., Quorum quenching by an N-acyl-homoserine lactone acylase from Pseudomonas aeruginosa PAO1. Infect. Immun. 74 (2006), 1673–1682.
83. Sköld, O., Penicillins and Other Betalactams. Antibiotics and Antibiotic Resistance. 2011, John Wiley & Sons, Inc, 69–94.
84. Smith, R., Coast, J., The true cost of antimicrobial resistance. BMJ, 346, 2013, f1493.
85. Stepper, J., Shastri, S., Loo, T.S., Preston, J.C., Novak, P., Man, P., Moore, C.H., Havlicek, V., Patchett, M.L., Norris, G.E., Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins. FEBS Lett. 585 (2011), 645–650.
86. Strahilevitz, J., Jacoby, G.A., Hooper, D.C., Robicsek, A., Plasmid-mediated quinolone resistance: a multifaceted threat. Clin. Microbiol. Rev. 22 (2009), 664–689.
87. Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C.M., Knight, R., Gordon, J.I., The human microbiome project. Nature 449 (2007), 804–810.
88. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J.F.W.M., Tijssen, J.G.P., Speelman, P., Dijkgraaf, M.G.W., Keller, J.J., Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl J. Med. 368 (2013), 407–415.
89. Vincent, P.A., Morero, R.D., The structure and biological aspects of peptide antibiotic microcin J25. Curr. Med. Chem. 16 (2009), 538–549.
90. Vintiñi, E., Villena, J., Alvarez, S., Medina, M., Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin. Exp. Immunol. 159 (2010), 351–362.
91. Volzing, K., Borrero, J., Sadowsky, M.J., Kaznessis, Y.N., Antimicrobial peptides targeting Gram-negative pathogens, produced and delivered by lactic acid bacteria. ACS Synth. Biol. 2 (2013), 643–650.
92. Walsh, C.T., Wencewicz, T.A., Prospects for new antibiotics: a molecule-centered perspective. J. Antibiot. 67 (2014), 7–22.
93. Wang, S., Li, Y., Shi, H., Scarpellini, G., Torres-Escobar, A., Roland, K.L., Curtiss, R. 3rd, Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect. Immun. 78 (2010), 3258–3271.
94. Wood, T.K., Knabel, S.J., Kwan, B.W., Bacterial persister cell formation and dormancy. Appl. Environ. Microbiol. 79 (2013), 7116–7121.
95. World Health Organization, Antimicrobial Resistance: Global Report on Surveillance., 2014, WHO, Geneva, Switerland.
96. World Health Organization, Global Antimicrobial Resistance Surveillance System: Manual for Early Implementation. 2015, WHO, Geneva, Switerland.
97. Wu, H.-C., Tsao, C.-Y., Quan, D.N., Cheng, Y., Servinsky, M.D., Carter, K.K., Jee, K.J., Terrell, J.L., Zargar, A., Rubloff, G.W., Payne, G.F., Valdes, J.J., Bentley, W.E., Autonomous bacterial localization and gene expression based on nearby cell receptor density. Mol. Syst. Biol., 9, 2013.
98. Xin, W., Wanda, S.-Y., Zhang, X., Santander, J., Scarpellini, G., Ellis, K., Alamuri, P., Curtiss, R., The Asd(+)-DadB(+) dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine. Infect. Immun. 80 (2012), 3621–3633.
99. Yim, G., Thaker, M.N., Koteva, K., Wright, G., Glycopeptide antibiotic biosynthesis. J. Antibiot. 67 (2014), 31–41.
100. Yosef, I., Manor, M., Kiro, R., Qimron, U., Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 7267–7272.